The 86th API China:

All rights reserved ©  Reed Sinopharm Exhibitions Co., Ltd.    京ICP备06050757号                                                                                    Website building:Powered By Beijing

International Sales and marketing:

Evan Wang 010-84556692





Pharmaceutical Production and Marketing Report Series 2: Production of Chemical Pharmaceutical Industry

China Pharmaceutical Industry Association
2020/08/25 17:14

I. General Situation

In 2019, transformation and upgrading of pharmaceutical enterprises were carried out, and some pharmaceutical enterprises increased their investment in emerging pharmaceutical fields. Leading enterprises integrated small- and medium-sized entrepreneurial enterprises, to enrich the industrial chain, enhance their global competitiveness. Pharmaceutical enterprises have made outstanding innovative achievements, and many Class I new drugs were approved and listed. In 2019, the cumulative added value of the pharmaceutical industry increased by 6.6% year on year. However, transformation of the pharmaceutical industry is facing great challenges: rising costs, strict drug registration standards, consistency evaluation, growing clinical trial costs, which all significantly increase enterprises’ expenditures. Environmental protection and taxation law, enhanced pollution prevention and control standards, and higher environmental protection costs are the current challenges for enterprises.
The Chinese central government has established the concept of respecting and protecting nature, and set the right balance between environmental protection and economic development. In this context of strict environmental protection standards and control, chemical API production in 2019 was carried out well. According to Statistics Information Special Committee of China Pharmaceutical Industry Association, the output of 24 major chemical APIs in 2019 increased by 8% year on year, and the export increased by 24.7% year on year. The output and export in the same period last year witnessed year-on-year decreases of 4.1% and 2.6%, respectively. 
In 2019, the output and export of anti-infective drugs increased by 1.8% and 4.1% year on year, respectively. The output of antipyretic analgesics increased by 9.4% year on year, but its export decreased by 1.2%. The output of vitamin and mineral drugs increased by 7.1% and their export increased by 33%. The output of anti-tumor drugs decreased by 26.2% year on year, and the export increased by 95.2%. The output of cardiovascular drugs increased by 9.1% year on year, while the export decreased by 3.8%.
Deepening of the national medical system reform introduced centralized drug bidding, batch procurement, medical insurance control, and antibiotic usage control, which impacted pharmaceutical production. According to Statistics Information Special Committee of China Pharmaceutical Industry Association, among the five major chemical preparations, the output of powder injection (including lyophilized injection powder) in 2019 decreased by 8.5%, injection decreased by 10%, infusion decreased by 2.1%, tablet increased by 4.4%, sustained-release tablet decreased by 9.4%, and capsule increased by 7%.

For business contact:

Mr. Evan

Tel: +86 010 8455 6692

Mob: +86 185 1324 5331 (WeChat & Whatsapp)